Microsatellite instability in colorectal cancer—the stable evidence

[1]  M. Ducreux,et al.  Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. , 2003, Cancer research.

[2]  I. Screpanti,et al.  Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability , 2004, Oncogene.

[3]  G. Parmigiani,et al.  Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomothearapy , 2009, Radiation oncology.

[4]  C. Amos,et al.  Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients , 2001, British Journal of Cancer.

[5]  M. Ligtenberg,et al.  Deficient mismatch repair system in patients with sporadic advanced colorectal cancer , 2009, British Journal of Cancer.

[6]  Shin Sasaki,et al.  Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. , 2006, Cancer research.

[7]  L. Aaltonen,et al.  BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing , 2004, Journal of Medical Genetics.

[8]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[9]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[10]  R. Gafà,et al.  Microsatellite Instability and Colorectal Cancer Prognosis , 2005, Clinical Cancer Research.

[11]  D. Schaid,et al.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.

[12]  A. Bardelli,et al.  Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. , 2005, Cancer research.

[13]  L. Aaltonen,et al.  A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition , 2006, Nature Genetics.

[14]  Y. Nakamura,et al.  Allelotype of colorectal carcinomas. , 1989, Science.

[15]  M. Yasuno,et al.  PIK3CA mutation is predictive of poor survival in patients with colorectal cancer , 2007, International journal of cancer.

[16]  C Hill,et al.  Interpretation of microarray data in cancer , 2007, British Journal of Cancer.

[17]  B. Leggett,et al.  Promoter Hypermethylation Frequency and BRAF Mutations Distinguish Hereditary Non-Polyposis Colon Cancer from Sporadic MSI-H Colon Cancer , 2004, Familial Cancer.

[18]  J. Cubiella,et al.  Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer , 2005, Gut.

[19]  C Caldas,et al.  Molecular classification of solid tumours: towards pathway-driven therapeutics , 2009, British Journal of Cancer.

[20]  Peter Kraft,et al.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Pierre Laurent-Puig,et al.  Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.

[22]  J. Jiricny.  The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.

[23]  T. Ørntoft,et al.  Gene expression signatures for colorectal cancer microsatellite status and HNPCC , 2005, British Journal of Cancer.

[24]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[25]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[26]  E CARBONETTO,et al.  [Colon Cancer]. , 1958, El Dia medico.

[27]  Suet Yi Leung,et al.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.

[28]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[29]  G. Deng,et al.  BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.

[30]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[31]  B. Iacopetta,et al.  CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Pollack,et al.  A gene expression signature of genetic instability in colon cancer. , 2005, Cancer research.

[33]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[34]  L. Laghi,et al.  Differences and evolution of the methods for the assessment of microsatellite instability , 2008, Oncogene.

[35]  David Joseph,et al.  Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer , 2000, The Lancet.

[36]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[37]  Darryl Shibata,et al.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.

[38]  R. Houlston,et al.  Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Compton,et al.  Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. , 2004, Cancer research.

[40]  Y. Pommier.  Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.

[41]  K. Kinzler,et al.  The Genetic Basis of Human Cancer , 1997 .

[42]  R. Labianca,et al.  Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Xia Han,et al.  Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity , 2004, Molecular Cancer.

[44]  M. Andreu,et al.  Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. , 2005, JAMA.

[45]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[46]  T. Sellers,et al.  Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology , 2008, Clinical Cancer Research.

[47]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[48]  A. Duval,et al.  Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. , 2002, Cancer research.

[49]  A. Benson,et al.  Adjuvant therapy in stage II colon cancer: current approaches. , 2005, The oncologist.

[50]  D. Coradini,et al.  PIK3CA cancer mutations display gender and tissue specificity patterns , 2008, Human mutation.

[51]  Linda Mol,et al.  Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2007, The Lancet.

[52]  L. V. van't Veer,et al.  Clinical application of the 70-gene profile: the MINDACT trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Boland,et al.  Cellular effects of CPT‐11 on colon carcinoma cells: Dependence on p53 and hMLH1 status , 2002, International journal of cancer.

[54]  T. Sauerbruch,et al.  Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer , 2006, International Journal of Colorectal Disease.

[55]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[56]  S. Gruber,et al.  Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  R. Labianca,et al.  Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Y. Yamashita,et al.  Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas , 2004, International journal of cancer.

[59]  R. Labianca,et al.  Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials , 2008 .

[60]  S. Bull,et al.  Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.

[61]  J. Abubaker,et al.  Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population , 2007, Oncogene.

[62]  J. Potter,et al.  Associations between Smoking, Alcohol Consumption, and Colorectal Cancer, Overall and by Tumor Microsatellite Instability Status , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[63]  Timothy J. Yeatman,et al.  DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers , 2008, Clinical Cancer Research.

[64]  Sabine Tejpar,et al.  Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial , 2010 .

[65]  B. Bellosillo,et al.  A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[66]  B. Uzzan,et al.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. , 2009, European journal of cancer.

[67]  King-Jen Chang,et al.  High‐frequency microsatellite instability predicts better chemosensitivity to high‐dose 5‐fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection , 2002, International journal of cancer.

[68]  J. Baselga,et al.  Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines , 2008, British Journal of Cancer.

[69]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  S N Thibodeau,et al.  Microsatellite instability in cancer of the proximal colon. , 1993, Science.

[71]  N. Matsubara,et al.  Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  S. Paik,et al.  Development of the 21-gene assay and its application in clinical practice and clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Choti,et al.  NCCN Clinical Practice Guidelines in Oncology: colon cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[74]  C. Compton,et al.  Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  A. Duval,et al.  Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability , 2007, Oncogene.

[76]  C. Boland,et al.  Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.

[77]  S. Gruber,et al.  Phenotype of Microsatellite Unstable Colorectal Carcinomas: Well‐Differentiated and Focally Mucinous Tumors and the Absence of Dirty Necrosis Correlate With Microsatellite Instability , 2003, The American journal of surgical pathology.

[78]  P. Loehrer.  Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2008 .

[79]  S. Schwartz,et al.  BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency , 2003, Oncogene.

[80]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[81]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[82]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[83]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[84]  Edward L. Lee,et al.  Distinct BRAF (V600E) and KRAS Mutations in High Microsatellite Instability Sporadic Colorectal Cancer in African Americans , 2009, Clinical Cancer Research.

[85]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Norman Wolmark,et al.  Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  R. Kittles,et al.  High incidence of microsatellite instability in colorectal cancer from African Americans. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[89]  S. Gruber.  New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. , 2006, Gastroenterology.

[90]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[91]  G. Mufti,et al.  Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[93]  H. Morreau,et al.  Diagnostic Approach and Management of Lynch Syndrome (Hereditary Nonpolyposis Colorectal Carcinoma): A Guide for Clinicians , 2006, CA: a cancer journal for clinicians.

[94]  Bhramar Mukherjee,et al.  Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. , 2009, Gastroenterology.

[95]  B. Uzzan,et al.  Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. , 2009, Anticancer research.

[96]  Bhramar Mukherjee,et al.  Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway , 2009, Clinical Cancer Research.

[97]  M. Loda,et al.  p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803 , 2009, Clinical Cancer Research.

[98]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[99]  L. Aaltonen,et al.  Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. , 2000, Gastroenterology.

[100]  A. Cox,et al.  Thymidine Selectively Enhances Growth Suppressive Effects of Camptothecin/Irinotecan in MSI+ Cells and Tumors Containing a Mutation of MRE11 , 2008, Clinical Cancer Research.

[101]  F. Praz,et al.  The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. , 2001, Cancer research.

[102]  永坂 岳司,et al.  Hypermethylation of O[6]-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases , 2004 .

[103]  Norman Wolmark,et al.  Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.